Custom DNA Oligos Market Size, Share, & Industry Analysis, By Type (PCR Oligos, Long Oligos, NGS-Oligos, cGMP Oligos, and Others), By Format, (Tubes and Plates) By Application (Molecular Biology Research, Drug Discovery, Diagnostics, and Others), By End User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, and Others), and Regional Forecast, 2026-2034

The global custom DNA Oligos market is witnessing significant growth due to increasing adoption of DNA synthesis for therapeutic applications and molecular diagnostics. Various established players are focusing on strategic activities such as collaborations to discover new applications of DNA oligos in therapeutics. Such factors are expected to bolster the demand for customized DNA oligos as per the research needs. Such factors are boosting the growth of the global custom DNA oligos market. 

• For instance, in June 2024, GSK plc. acquired Elsie Biotechnologies for up to USD 50.0 million. This acquisition integrated Elsie’s oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK’s platform R&D capabilities. 

Oligonucleotides, also known as oligos, primers, and probes, are short strands of DNA or RNA molecules that are linked to form a chain of nucleotide bases. Custom DNA oligos are synthesized with sequences specified by the user, customized to each application. These custom-based DNA oligos are most commonly used in molecular diagnostics, synthetic biology, genetic sequencing, immunology, infectious disease, clinical, research, pharma, and even therapeutic applications for targeted drug delivery, gene therapy, and gene silencing, and many more. They are also used as primers for DNA sequencing and PCR reactions, as probes for hybridization assays in gene detection, as building blocks for the construction of synthetic genes, and as antisense molecules for the desired control of gene expression. Such diverse application fuels the growth of the global custom DNA oligos market.

Custom DNA Oligos Market Driver

Rising Investment in Research Initiatives for Novel Therapeutics to Result in Increasing Adoption of Custom DNA Oligos Services

Increasing investment for research and development to discover novel therapeutics for various diseases through gene therapies and personalized medicine. Custom DNA Oligos are essential for diagnostics, research, and other experiments for drug discovery. With rising research initiatives, the utilization of biotech tools such as PCR techniques and NGS sequencing also rises to further contribute to market growth.

• For instance, in December 2022, the U.K. Government invested USD 113.6 million to initiate a research study focusing on the effectiveness of using whole genome sequencing to treat rare genetic diseases in newborn babies. Genomics England led this research in partnership with the NHS to boost genomics research in U.K. 

Average Funding for National Genomic Program, By Key Organizations (in USD millions)

According the data published in The American Journal of Human Genetics, it was reported that National Human Genome Research Institute (NHGRI) invested USD 607.9 million in their national genomics program.

Custom DNA Oligos Market Restraint

Challenges of Product Stability Due to Nuclease Degradations and Limited Infrastructure for Storage to Hamper Market Growth

These DNA Oligos are required to be stored at optimum temperatures and are prone to nuclease degradation in absence of proper storage conditions. 

• For instance, in April 2024, NIH published an article titled ‘Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes’ that urged to standardized stability of oligonucleotides for reference to researchers, enabling them to compare the impact of various modifications on oligo stability and assess the degradation kinetics effectively.

Additionally, these custom DNA oligos are subjected to the risk of degradation in transit, and the limited infrastructure for proper storage facilities could hamper the market growth.

Custom DNA Oligos Market Opportunity

Development of Personalized Medicine Tailored to Meet Patient Demand Offers a Lucrative Market Growth Opportunity 

With the advent of precision medicine, there is a growing need for customized DNA oligonucleotides to cater to individual patient profiles. These personalized oligonucleotides play a crucial role in diagnostics, targeted therapies, and companion diagnostics. Personalized medicine has various applications, such as gene therapies offer lucrative growth opportunities for the custom DNA Oligos market. 

• For instance, according to the U.K.’s Department of Business and Trade, the U.K. government is increasing public spending by USD 27.36 billion by 2025 to focus more on precision medicine opportunities. Also, the government’s 2.4% GDP will be spent on research and development by 2027. Such rising spending for the development of novel therapeutics in personalized medicine is expected to offer market growth. 

Key Insights

The report covers the following key insights:

• Overview: Application of Custom DNA Oligos
• Technological Advancements in the Market
• Pricing Analysis, By Key Service Offerings, By Key Players
• Key Industry Development (Mergers, Acquisitions, Partnerships, Others)

Segmentation

Analysis by Type

On the basis of type, the global custom DNA oligos market is segmented into PCR oligos, long oligos, NGS-oligos, cGMP oligos, and others.

Among these, PCR oligos are expected to hold a substantial market share. PCR oligos are short, single-stranded DNA molecules essential for the polymerase chain reaction (PCR) techniques. They act as starting points for DNA replication by DNA polymerase, enabling the amplification of specific DNA sequences. High utilization of PCR techniques is expected to bolster the segmental growth. 

• For Instance, in September 2022, Integrated DNA Technologies launched the PrimeTime 1-Step 4X Broad-Range qPCR Master Mix. The unique blend in the master mix was ideal for viral research and other gene expression applications. This feature eliminated the need for the extraction step. This supported the growing need for an inhibitor-resistant, high-performance master mix in PCR techniques that allowed direct amplification of crude samples.

Analysis by Format

By format, the market is divided into tubes and plates.

Plates are expected to hold a considerable market share in the global custom DNA Oligos market. Custom DNA oligos are either supplied in tubes for smaller and focused experiments, whereas plates are more suitable for high-throughput applications such as PCR and next-generation sequencing. Thus, high demand for these biotech tools in turn heightens the demand for DNA oligos in plate format.

• For example, various pharmaceutical and biotech companies require large quantities of long custom oligonucleotides to carry out research for specific requirements. Such large numbers of mainly unmodified, moderately long standard oligos are delivered in microtiter plate formats (96-well plate) to suit the requirements of increasingly popular genomic screening/microarray programs. These factors are expected to drive the segmental growth. 

Analysis by Application

By application, the market is divided into molecular biology research, drug discovery, diagnostics, and others.

The molecular biology research segment is expected to generate a significant revenue share in the global custom DNA oligos market. The molecular biology research requires custom DNA oligonucleotides in large quantities due to their utilization for research tools such as quantitative PCR (qPCR), gene editing, assays, and site-directed mutagenesis. All these tools require custom DNA oligos to be synthesized with user-specified sequences. Moreover, the advancements in technology for these tools are expected to drive the segmental growth in the custom DNA oligos market. 

• For instance, in November 2024, QIAGEN launched novel tools for customizing digital PCR assays and NGS panels for microbial analysis. Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels can be used to support microbial analysis of bacterial, fungal, and viral targets. These new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system.

Analysis by End User

By end user, the market is divided into pharmaceutical and biotechnology companies, research and academic institutes, and others.

Pharmaceutical and biotechnological companies are expected to hold a significant share in the global custom DNA oligos market. Intensive research is carried out by established pharmaceutical and biotechnological companies to expand the applications of these DNA oligonucleotides in therapeutic applications.

Additionally, these custom-based DNA oligonucleotides are extensively used in biotech tools such as next-generation sequencing, which have wide applications in personalized medicine and clinical diagnostics to further augment the market share.

• For instance, in February 2024, Integrated DNA Technologies, Inc. partnered with Element Biosciences, Inc. to launch new IDT xGen NGS products designed for Element’s AVITI System. This system is equipped with differentiated NGS tools to support a wide range of NGS applications in drug discovery.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global custom DNA oligos market in 2024. The high share of the region in the market is attributed to robust research infrastructure, substantial investment in novel research. Such factors augment the requirement for the custom DNA oligos market, thus contributing to market growth in the region.

• For instance, in January 2025, Foresee Genomics, a Next Generation Sequencing (NGS) solutions company, raised USD 1.3 million in SAFE (Simple Agreement for Future Equity) financing for advancement in NGS for small and medium-sized labs. The company 

Additionally, the presence of prominent players such as Integrated DNA Technologies, Inc., Eurofins Genomics LLC, and Azenta US Inc., in the region is also supporting the regional growth. 

Europe is expected to grow with a significant market share in the forecasted period. The regional growth of the custom DNA oligos is attributed to the strategic collaboration of the established players to enhance their production capacities and expand product offerings. 

• For instance, in May 2024, Integrated DNA Technologies, Inc. collaborated with Molecular to integrate its next-generation sequencing (NGS) capabilities. The partnership paired IDT’s Archer NGS research assay platform with Molecular Health’s variant annotation and reporting software to equip molecular researchers with tertiary analysis for their NGS data.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to various initiatives by key industry players streamlining focus on the expansion of production capacity of the custom DNA oligos market.

• For instance, in May 2023, GenScript expanded its manufacturing facility for Oligonucleotide and peptide production in China. This expanded oligonucleotide synthesis capability offered qPCR oligos, NGS oligos, RNA oligos, DNA oligos, and more to support a wide range of applications, ranging from molecular diagnostics to genome editing. 

Key Players covered

The global custom DNA oligos market reflects a fragmented competitive structure with the presence of major players. The report includes the profiles of the following key players.

• Integrated DNA Technologies, Inc. (U.S.)
• DH Life Sciences, LLC. (U.S.)
• Eurofins Genomics LLC (U.S.)
• Azenta US Inc. (GENEWIZ) (U.S.)
• Merck KGaA (Germany)
• Cell Signaling Technology, Inc. (U.S.)
• Gene Link (U.S.)
• GENERI BIOTECH (Czech Republic)
• LGC Biosearch Technologies (U.K.)

Key Industry Developments

• In March 2023, Oligo Factory unveiled its new oligo manufacturing facility in Holliston, U.S. This development increased the production capacity of the company 12-fold.